Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. - Wikidata - awgldk - TriplyDB

Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.

Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.

http://www.wikidata.org/entity/Q33370115

about

Maintenance bioimmunotherapy for epithelial ovarian cancer Ovarian cancer (advanced)Have we overestimated the benefit of human(ized) antibodies?The potential and hurdles of targeted alpha therapy - clinical trials and beyond.Radioimmunotherapy with α-particle-emitting radionuclides.Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies.Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.Cancer radioimmunotherapy.Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.Transmembrane mucins as novel therapeutic targets Monoclonal antibodies in gynecological cancer: a critical point of view.Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model.Radiolabelled monoclonal antibodies in the treatment of metastatic cancer Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".The MUC1 Ectodomain: A Novel and Efficient Target for Gold Nanoparticle Clustering and Vapor Nanobubble Generation Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis Application of (212)Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation.GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012.Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis Natural and Induced Humoral Responses to MUC1.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential Emerging trends for radioimmunotherapy in solid tumors Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer.Therapeutic targets and new directions for antibodies developed for ovarian cancer.Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice.Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.MUC1 immunotherapy.Radioimmunotherapy of solid tumors: searching for the right target.Molecular targeted therapy in ovarian cancer: what is on the horizon?Ovarian cancer stem cells: elusive targets for chemotherapy.The new golden era for radioimmunotherapy: not just for lymphomas anymore.Monoclonal antibodies therapies for ovarian cancer.Radioimmunotherapy for peritoneal cancers.The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.General overview of radioimmunotherapy of solid tumors.Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy.Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.Update on Mucin-1 immunotherapy in cancer: a clinical perspective.

P2860

Q24234761-352FB50B-8FA4-4126-970D-AF53DE8F1E50 Q34010642-2972AA83-D5D3-48CC-AF55-6449F7922AAE Q34142714-8270774C-0875-4FD7-9A80-58584FEF7581 Q34399879-E4977CD5-0396-466D-A19D-26A09DCBAB1B Q34419562-A533B0F5-2AF4-4D14-B3E5-6BF0E1A8E550 Q34841141-B772D999-266B-41C0-AB26-1AC479A495AB Q34903258-110CDC16-8722-46C5-9DA6-CA7C8CE18E5B Q35070045-8821E262-4F40-4AA4-832C-60995D54AB2B Q35509695-7EA7F082-AEF5-4DB6-8543-CE60996FD97B Q35564007-8EF76FFD-B326-4777-A545-E77DB8369781 Q35632645-4A8C16A8-3C39-4916-B08B-50CA98D83EBF Q35659915-78CC6EAD-B35F-4FFC-B9D3-26C042F34530 Q35675494-222E7C38-3916-4A0F-A9F6-61B8B86ABC6A Q35840380-8026FEE9-96D5-4181-9BC8-4F86CD3B7787 Q35880923-EA2C7709-27AC-4E10-8E0D-CD3B5FDF907E Q36181659-8B031AF8-93E2-4BC6-9DD2-3170CC723E23 Q36387694-DC491342-1B73-4CFB-961B-FC2EE6BEFE7D Q36551498-7F7DAC48-F042-45E9-A68C-D96F783F6CDB Q36962482-57744AF5-3BC0-4247-876F-51EFAC1FD11A Q37086928-66B32E23-1C83-4E8D-8CD1-B963171FF183 Q37137385-73D081FD-CB9D-4193-8ABA-4E55043323D4 Q37174938-D515B125-DC7B-4D93-9B1D-E4DC3B9B3891 Q37193096-60A3DC4A-6D6E-4F08-AA52-D0861A21D173 Q37222795-D5C15C23-AF2E-44AA-94FD-1F170F5344E7 Q37326840-A00C76C7-01BD-465A-805A-1AFEF61BC54F Q37397674-B7474FA6-4FCA-4C2D-8720-E722702E320E Q37397869-4D518D9E-3CFD-49C9-A0CB-8AFC407BAEE9 Q37406628-74838EBE-70A5-4D35-9CE2-0FB151068CE2 Q37773241-934A8987-F8E1-452C-819B-4FDA5D402BC7 Q37804904-77549628-7C4A-44BB-A1ED-023469D51056 Q37888659-C78EF1E4-2025-4820-AC74-6B4CE8CE975D Q38013671-8F4EEBD6-640B-41BB-8301-DCD56A760764 Q38072815-23E4FF92-1F0B-4075-B5E7-7DF16F35F95D Q38078400-805AEDFE-E507-4020-8132-CEF02A3E30D0 Q38096059-0E3551E2-FB91-450A-8D85-66F874B35B7C Q38100999-CA1CC348-4BF0-4630-94DA-B40BB65C8258 Q38103579-67CD923A-751D-4148-9651-E02E555924FB Q38142315-36754E5E-B410-4191-8083-00A731322FB2 Q38230884-901A3048-34F3-4EA4-A278-9ED96DD8B087 Q38603410-F971D0AA-47AC-432E-A9FD-7CAB12064126

P2860

Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.

http://www.wikidata.org/entity/Q33370115

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Phase III trial of intraperito ...... ly defined complete remission.

@ast

Phase III trial of intraperito ...... ly defined complete remission.

@en

type

label

Phase III trial of intraperito ...... ly defined complete remission.

@ast

Phase III trial of intraperito ...... ly defined complete remission.

@en

prefLabel

Phase III trial of intraperito ...... ly defined complete remission.

@ast

Phase III trial of intraperito ...... ly defined complete remission.

@en

P1433

Q33370115-0BF27181-F1CE-4C7D-8099-F283AEEA2617

P1476

Q33370115-2BF7C6BF-9483-493C-951A-D4216FF52A23

P2093

Q33370115-10FF5A48-E434-45AA-8D52-1E79A77CA6C5

Q33370115-1ABFD9BC-C684-4238-AEE3-400B52739C46

Q33370115-1E8315C7-3947-47D0-A205-80C75B713A46

Q33370115-46628C2E-F7C0-4A9E-882E-5BBE48B874AB

Q33370115-51403A1F-7435-4171-829B-16121342B45E

Q33370115-673B2531-4E37-47D0-AF14-781597EA3726

Q33370115-67B9BCBB-6FBB-4550-B6D4-4A13D8BE02DA

Q33370115-6FBD1877-1D3A-4A0D-ACF0-AF1F425CEF20

Q33370115-7523E745-28FB-4BE0-83F3-52810EDE1DB4

Q33370115-7B0DFD76-072E-432B-B25C-9F34FA1D2FB4

P304

Q33370115-55007FAC-A10E-43EC-A426-84DBBE245EE3

P31

Q33370115-C5D721FE-D497-4C5C-AFAC-35178BD14E8C

P356

Q33370115-819A3A45-9E23-4A5B-8382-1E3306D92DF8

P407

Q33370115-C8B18E43-CCAD-4BF0-864F-DD9867B4CF9B

P433

Q33370115-6C4C6336-01C4-4EF0-BF95-42D1C1C327E6

P478

Q33370115-861487CA-34E4-4032-93C7-BFBAEE694E4D

P577

Q33370115-5FC07682-836F-4D6E-BCE4-1E66F5F63130

P698

Q33370115-05C211C2-997D-4E6F-A6E5-4AC09BCC8EF5

P921

Q33370115-61805A78-36D1-4C4A-A6B5-D4F9226D1F88

Q33370115-6CACF502-F5D2-471E-BF78-16EA63F84470

Q33370115-78D883D3-D0CD-4BF3-BBC8-44B12AD0E663

P356

JCO.2005.02.5973

P1433

Journal of Clinical Oncology

P1476

Phase III trial of intraperito ...... ly defined complete remission.

@en

P2093

Agamemnon A Epenetos

http://www.w3.org/2001/XMLSchema#string

Alberto Lopes

http://www.w3.org/2001/XMLSchema#string

Benedict B Benigno

http://www.w3.org/2001/XMLSchema#string

Dennis Thurston

http://www.w3.org/2001/XMLSchema#string

Gordon Stamp

http://www.w3.org/2001/XMLSchema#string

Gregory Spiegel

http://www.w3.org/2001/XMLSchema#string

Janica Markowska

http://www.w3.org/2001/XMLSchema#string

Joanna Lambert

http://www.w3.org/2001/XMLSchema#string

John T Soper

http://www.w3.org/2001/XMLSchema#string

Leon F Massuger

http://www.w3.org/2001/XMLSchema#string

P304

571-578

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.02.5973

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16446329

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial